Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-11-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.00.3863PMID 16230677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of oxaliplatin in patients with advanced cancer

  2004cited by this paper
• Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.

  2003cited by this paper
• Oxaliplatin–5-Fluorouracil and Ionizing Radiation

  2003cited by this paper
• Chemoradiation with novel agents for rectal cancer.

  2002cited by this paper
• Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial.

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).

  2001cited by this paper
• Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.

  2001cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

  2001cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx.

  2000cited by this paper
• Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.

  2000cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results.

  1999cited by this paper
• Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma.

  1999cited by this paper
• A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma

  1999cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• Oxaliplatin: mechanism of action and antineoplastic activity.

  1998cited by this paper
• The role of chemotherapy in the management of nasopharyngeal carcinoma

  1998cited by this paper
• Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx.

  1998cited by this paper
• Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

  1998cited by this paper
• Combined-modality therapy for head and neck cancer.

  1997cited by this paper
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

  1996cited by this paper
• Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  1996cited by this paper
• Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival.

  1996cited by this paper
• Nasopharyngeal cancer: epidemiology, staging, and treatment.

  1994cited by this paper
• Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan.

  1993cited by this paper
• Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure.

  1992cited by this paper
• Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the princess margaret hospital experience

  1991cited by this paper
• Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.

  1991cited by this paper
• Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.

  1990cited by this paper
• High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy.

  1990cited by this paper
• Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1302 patients.

  1989cited by this paper
• Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1302 patients.

  1989cited by this paper
• Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

  1989cited by this paper
• Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study.

  1988cited by this paper
• Excellent Response to cis‐Platinum–Based Chemotherapy in Patients with Recurrent or Previously Untreated Advanced Nasopharyngeal Carcinoma

  1988cited by this paper
• Antitumor activity of l-OHP in mice.

  1985cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• An epidemiologic and clinical study of nasopharyngeal carcinoma.

  1978cited by this paper
• A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship

  1970cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers.

  2025cites this paper
• Concurrent chemoradiotherapy with S-1 versus platinum in the treatment of locoregionally advanced nasopharyngeal carcinoma: a multicenter, retrospective, propensity score-matched analysis

  2024cites this paper
• Osteoradionecrosis Rates Following Head and Neck Radiotherapy: Beyond the Numbers.

  2024cites this paper
• CACA guidelines for holistic integrative management of nasopharyngeal carcinoma

  2023cites this paper
• Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma

  2023cites this paper
• Efficacy of concurrent chemoradiotherapy alone for loco-regionally advanced nasopharyngeal carcinoma: long-term follow-up analysis

  2023cites this paper
• Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

  2023cites this paper
• Comparison the Acute Toxicity of Two Different Induction Chemotherapy Schedules with Cisplatin and Fluorouracil in Nasopharyngeal Carcinoma Patients.

  2023cites this paper
• A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone

  2022cites this paper
• Bioinformatics analysis identifies potential biomarkers involved in the metastasis of locoregionally advanced nasopharyngeal carcinoma

  2022cites this paper
• MRI-based radiomics models can improve prognosis prediction for nasopharyngeal carcinoma with neoadjuvant chemotherapy.

  2022cites this paper
• The effect of combined TPF and intensity modulated radiotherapy after TPF induction chemotherapy on locally advanced nasopharyngeal carcinoma: a retrospective analysis.

  2021cites this paper
• The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

  2021cites this paper
• Differences in Radiomics Signatures Between Patients with Early and Advanced T‐Stage Nasopharyngeal Carcinoma Facilitate Prognostication

  2021cites this paper
• Combined radiotherapy and chemotherapy versus radiotherapy alone in elderly patients with nasopharyngeal carcinoma

  2021cites this paper
• Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

  2021cites this paper
• Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.

  2021cites this paper
• Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial

  2021cites this paper
• A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma—To Know, Then to Measure

  2020cites this paper
• Cancer of the Head and Neck

  2020cites this paper
• Therapeutic patterns and outcomes in older patients (aged ≥65 years) with stage II-IVB Nasopharyngeal Carcinoma: an investigational study from SEER database

  2020cites this paper
• Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years)

  2019cites this paper
• Radiomics and Machine Learning for Radiotherapy in Head and Neck Cancers

  2019cites this paper
• Head and Neck Cancers

  2019cites this paper
• CMAR_A_197544 6365..6376

  2019cites this paper
• Long-Term Survival and Prognostic Factors in Locoregionally Advanced Nasopharyngeal Carcinoma Patients Treated with TPF Induction Chemotherapy followed by Cisplatin-Combined Concurrent Chemoradiotherapy

  2019influential citation
• Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.

  2019cites this paper
• Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.

  2019cites this paper
• Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives

  2019cites this paper
• Evolutionary role of chemotherapy in advanced nasopharyngeal carcinoma: a literature-based network meta-analysis

  2019cites this paper
• Toxicities of chemoradiotherapy and radiotherapy in nasopharyngeal carcinoma: an updated meta-analysis

  2019influential citation
• The Changing Role of Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Updated Systemic Review and Network Meta-Analysis

  2018cites this paper
• Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma

  2018cites this paper
• Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area

  2018cites this paper
• Comparison Long-term Outcome of Definitive Radiotherapy plus Different Chemotherapy Schedules in Patients with Advanced Nasopharyngeal Carcinoma

  2018cites this paper
• Concurrent Chemoradiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma: Treatment Outcomes and Prognostic Factors

  2018cites this paper
• Comparison the clinical outcomes with altered versus conventional fractionated radiotherapy plus concurrent chemotherapy for advanced nasopharyngeal carcinoma

  2018cites this paper
• Clinical and prognostic analyses of 110 patients with N3 nasopharyngeal carcinoma

  2018cites this paper
• Prognostic factors of nasopharyngeal carcinoma patients in a tertiary referral hospital: a retrospective cohort study

  2017cites this paper
• Induction Chemotherapy Has No Prognostic Value in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Chronic Hepatitis B Infection in the IMRT Era

  2017cites this paper
• Carcinoma of the Nasopharynx

  2017cites this paper
• Chemoradiotherapy enhanced the efficacy of radiotherapy in nasopharyngeal carcinoma patients: a network meta-analysis

  2017cites this paper
• Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma

  2017cites this paper
• The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: a Bayesian network meta-analysis of published randomized controlled trials

  2016cites this paper
• Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA

  2016cites this paper
• Advances in systemic treatment for nasopharyngeal carcinoma.

  2016cites this paper
• Nasopharyngeal carcinoma patients with retropharyngeal lymph node metastases: a minimum axial diameter of 6 mm is a more accurate prognostic predictor than 5 mm.

  2015cites this paper
• Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials.

  2015cites this paper
• Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies.

  2015cites this paper
• Progresses and Challenges in Chemotherapy for Loco- Regionally Advanced Nasopharyngeal Carcinoma.

  2015cites this paper
• Prognostic Value of Classifying Parapharyngeal Extension in Nasopharyngeal Carcinoma Based on Magnetic Resonance Imaging

  2015cites this paper
• The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy

  2015cites this paper
• Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy

  2015cites this paper
• Feasibility and Efficiency of Concurrent Chemo-Radiotherapy for Nasopharyngeal Carcinoma Patients

  2015cites this paper
• Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective.

  2015cites this paper
• Progress and Challenges in Chemotherapy for Loco-Regionally Advanced Nasopharyngeal Carcinoma

  2015cites this paper
• Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma

  2015cites this paper
• Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.

  2015cites this paper
• Sensorineural hearing loss following induction chemotherapy plus concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

  2015cites this paper
• A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.

  2015cites this paper
• Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy

  2015cites this paper
• Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials

  2015cites this paper
• Management of locally and regionally advanced nasopharyngeal carcinoma with chemoradiotherapy

  2014cites this paper
• Phase II clinical trial of hR 3 combined with radiotherapy in locally advanced nasopharyngeal carcinoma

  2014cites this paper
• Nasopharyngeal carcinoma: Current treatment options and future directions

  2014cites this paper
• [Nasopharyngeal cancers, an overview].

  2014cites this paper
• Phase II clinical trial of h-R3 combined with radiotherapy in locally advanced nasopharyngeal carcinoma.

  2014cites this paper
• Successful Treatment of Recurrent Metastatic Nasopharyngeal Carcinoma With Oxaliplatin and Doxorubicin

  2014cites this paper
• A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy , concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma

  2014cites this paper
• Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma

  2014cites this paper
• Concurrent chemoradiotherapy followed by adjuvant chemotherapy compared with concurrent chemoradiotherapy alone for the treatment of locally advanced nasopharyngeal carcinoma: a retrospective controlled study.

  2014cites this paper
• Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.

  2014cites this paper
• Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic.

  2014cites this paper
• Primary tumor regression speed after radiotherapy and its prognostic significance in nasopharyngeal carcinoma: a retrospective study

  2014cites this paper
• Primary tumor regression speed after radiotherapy and its prognostic significance in nasopharyngeal carcinoma: a retrospective study

  2014cites this paper
• Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area

  2014cites this paper
• Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches

  2014cites this paper
• Nasopharyngeal Carcinoma: Management Strategies

  2014cites this paper
• Five-year survival and median survival time of nasopharyngeal carcinoma in Hospital Universiti Sains Malaysia.

  2014cites this paper
• Nasopharyngeal cancers, an overview on behalf of the French Intergroupe ORL/GORTEC

  2014cites this paper
• The Evolving Role of Systemic Therapy in Nasopharyngeal Carcinoma: Current Strategies and Perspectives

  2013cites this paper
• Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.

  2013cites this paper
• Clinical prognostic factors in locally advanced nasopharyngeal carcinoma in Moroccan population.

  2013cites this paper
• Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma

  2013cites this paper
• Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma.

  2013cites this paper
• Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma

  2013cites this paper
• Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers

  2013cites this paper
• Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma

  2013cites this paper
• Progress report of a randomized trial comparing long‐term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China

  2013influential citation
• Targeting tumor hypoxia in nasopharyngeal carcinoma

  2013cites this paper
• Emerging treatment options for nasopharyngeal carcinoma

  2013cites this paper
• Phase I/II study of induction chemotherapy plus concurrent chemotherapy and SMART-IMRT-based radiotherapy in locoregionally-advanced nasopharyngeal cancer

  2013cites this paper
• Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.

  2013cites this paper
• Long‐term survival analysis of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA levels

  2013cites this paper
• The expression of epidermal growth factor receptor and Ki67 in primary and relapse nasopharyngeal cancer: a micro-evidence for anti-EGFR targeted maintenance therapy

  2012cites this paper
• Intensity-modulated radiation therapy for nasopharyngeal carcinoma: a review

  2012cites this paper
• Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy.

  2012cites this paper
• Risk factors for osteoradionecrosis after head and neck radiation: a systematic review.

  2012influential citation
• 2011 Young Surgeon's Award Winner: high endothelial venules: a novel prognostic marker in cancer metastasis and the missing link?

  2012cites this paper
• Current and emerging treatment options for nasopharyngeal carcinoma

  2012cites this paper